{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mavoglurant+%28AFQ056%29",
    "query": {
      "intervention": "Mavoglurant (AFQ056)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 18,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mavoglurant+%28AFQ056%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T04:30:17.864Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06136195",
      "title": "Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alcohol Consumption",
        "Heavy Drinker",
        "Alcohol Use Disorder (AUD)"
      ],
      "interventions": [
        {
          "name": "Mavoglurant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "21 Years to 50 Years"
      },
      "enrollment_count": 63,
      "start_date": "2024-07-01",
      "completion_date": "2028-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-09-30T04:30:17.864Z",
      "location_count": 2,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06136195"
    },
    {
      "nct_id": "NCT01482143",
      "title": "Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Fragile X Syndrome"
      ],
      "interventions": [
        {
          "name": "AFQ056",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "3 Years to 11 Years"
      },
      "enrollment_count": 21,
      "start_date": "2012-03",
      "completion_date": "2013-10",
      "has_results": false,
      "last_update_posted_date": "2020-12-08",
      "last_synced_at": "2026-09-30T04:30:17.864Z",
      "location_count": 3,
      "location_summary": "Sacramento, California • Chicago, Illinois • Nashville, Tennessee",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01482143"
    },
    {
      "nct_id": "NCT03327792",
      "title": "Mavoglurant in Alcohol Drinking",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alcohol Drinking"
      ],
      "interventions": [
        {
          "name": "Mavoglurant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "21 Years to 50 Years"
      },
      "enrollment_count": 34,
      "start_date": "2018-02-07",
      "completion_date": "2023-07-13",
      "has_results": true,
      "last_update_posted_date": "2024-08-06",
      "last_synced_at": "2026-09-30T04:30:17.864Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03327792"
    },
    {
      "nct_id": "NCT01433354",
      "title": "Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Fragile X Syndrome"
      ],
      "interventions": [
        {
          "name": "AFQ056",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "12 Years to 18 Years"
      },
      "enrollment_count": 119,
      "start_date": "2011-11",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2016-03-24",
      "last_synced_at": "2026-09-30T04:30:17.864Z",
      "location_count": 7,
      "location_summary": "Sacramento, California • Decatur, Georgia • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01433354"
    },
    {
      "nct_id": "NCT05203965",
      "title": "Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Familial Alcoholism Vulnerability"
      ],
      "interventions": [
        {
          "name": "Mavoglurant (AFQ056)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 78,
      "start_date": "2022-05-17",
      "completion_date": "2026-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-09-30T04:30:17.864Z",
      "location_count": 1,
      "location_summary": "Hartford, Connecticut",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05203965"
    },
    {
      "nct_id": "NCT01173731",
      "title": "Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson Disease",
        "Dyskinesia, Drug-Induced",
        "Levodopa"
      ],
      "interventions": [
        {
          "name": "AFQ056",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 66,
      "start_date": "2010-10",
      "completion_date": "2013-10",
      "has_results": false,
      "last_update_posted_date": "2020-12-23",
      "last_synced_at": "2026-09-30T04:30:17.864Z",
      "location_count": 3,
      "location_summary": "Sunnyvale, California • Englewood, Colorado • Indianapolis, Indiana",
      "locations": [
        {
          "city": "Sunnyvale",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01173731"
    },
    {
      "nct_id": "NCT01348087",
      "title": "Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fragile X Syndrome"
      ],
      "interventions": [
        {
          "name": "AFQ056",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 148,
      "start_date": "2011-08",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2016-05-25",
      "last_synced_at": "2026-09-30T04:30:17.864Z",
      "location_count": 10,
      "location_summary": "Phoenix, Arizona • Sacramento, California • Decatur, Georgia + 7 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01348087"
    },
    {
      "nct_id": "NCT01491932",
      "title": "Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dyskinesias",
        "Parkinson Disease",
        "Movement Disorders",
        "Parkinsonian Disorders",
        "Anti-Dyskinesia Agents"
      ],
      "interventions": [
        {
          "name": "AFQ056",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 129,
      "start_date": "2012-03",
      "completion_date": "2013-10",
      "has_results": false,
      "last_update_posted_date": "2020-12-23",
      "last_synced_at": "2026-09-30T04:30:17.864Z",
      "location_count": 3,
      "location_summary": "Englewood, Colorado • Kansas City, Kansas • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01491932"
    },
    {
      "nct_id": "NCT06273540",
      "title": "Phase1, STP7 Cocaine Drug-Drug Interaction Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cocaine Use Disorder"
      ],
      "interventions": [
        {
          "name": "STP7 (mavoglurant)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Cocaine Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stalicla SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 21,
      "start_date": "2024-04-15",
      "completion_date": "2024-10-07",
      "has_results": false,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-09-30T04:30:17.864Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06273540"
    },
    {
      "nct_id": "NCT03341715",
      "title": "Metabotropic Glutamate Receptor-5 (mGlur5) Effects on Reward-Related fMRI-BOLD Activation in FHP and FHN",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Familial Alcoholism Vulnerability"
      ],
      "interventions": [
        {
          "name": "Mavoglurant (AFQ056)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "18 Years to 35 Years"
      },
      "enrollment_count": 18,
      "start_date": "2018-06-01",
      "completion_date": "2019-11-13",
      "has_results": false,
      "last_update_posted_date": "2022-01-11",
      "last_synced_at": "2026-09-30T04:30:17.864Z",
      "location_count": 1,
      "location_summary": "Hartford, Connecticut",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03341715"
    }
  ]
}